Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 53.19

-1.4%

Dec 30 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Doc Bones	4/21/2005 8:45:38 AM
	Read Replies (1) of 52153

Pozen says migraine drug mets targets in trials Thu Apr 21, 2005 08:06 AM ET NEW YORK, April 21 (Reuters) - Pozen Inc. (POZN.O: Quote, Profile, Research) on Thursday said a migraine treatment it is developing with GlaxoSmithKline (GSK.L: Quote, Profile, Research) met all of its main targets in late-stage tests. It said it expects no additional trials will be needed to satisfy regulators. Pozen said it has met with U.S. regulators and discussed the results of both late-stage trials and other information required for a drug application. It expects to submit an application to market the drug, Trexima, with the U.S. Food and Drug Administration in the third quarter. The FDA rejected the drug's application last year because it was not more effective than existing treatments. yahoo.reuters.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next